Navigation Links
Therapure Biopharma Inc. announces collaboration with BioVectra Inc.
Date:11/4/2008

Canadian companies team up in specialty biologics development

TORONTO and CHARLOTTETOWN, Nov. 4 /PRNewswire/ - BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.

Over the past five years, BioVectra has been developing proprietary technologies for PEGylation as a mechanism for drug delivery. The partnership with Therapure builds upon BioVectra's expertise in the production of modified biologic molecules using a proprietary MPEG technology.

Therapure, from its 130,000 sq. ft facilities in Mississauga, Ontario, adds proprietary purification techniques and impressive formulation, fill, and finish expertise in biologics handling.

"We are very excited about working with BioVectra," said Thomas Wellner, President and CEO of Therapure Biopharma. "They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership."

"Our current program for drug development depends on finding the right partners," said Dale Zajicek, COO and VP of Business Development for BioVectra. "We know we have made a good choice in Therapure Biopharma and we look forward to working together to further the development and commercialization of this product."

About Therapure Biopharma:

Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. Therapure Biopharma acquired its Canadian-built and conceived facility from Hemosol Corporation, a specialist in therapies derived from hemoglobin, a blood protein. Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: http://www.therapurebio.com

About BioVectra Inc.:

BioVectra Inc. is a growing Canadian biopharmaceutical company focused on contract manufacturing and product development of active pharmaceutical ingredients, pharmaceutical intermediates, and specialized bioreagents. Located in Prince Edward Island, BioVectra currently holds 8 Drug Master File filings and is an active supplier to most of the major pharmaceutical, biotechnology, and diagnostic companies in North America and Europe.

For more information, please visit: http://www.biovectra.com


'/>"/>
SOURCE Therapure Biopharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Therapure Biopharma Inc. announces collaboration with Induce Biologics Inc.
2. Therapure Biopharma Inc. opens for business with first client contracts
3. Morria Biopharmaceuticals Plc to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. Helix BioPharma Corp. Announces Fiscal 2008 Results
5. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
6. CeNeRx BioPharma Completes $15 Million Series B Financing
7. Lilly Recognized as One of the Worlds Top Biopharmaceutical Employers
8. Millennium Ranks in the Top 10 Best Biopharma Employers in the World by Science Magazine
9. Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds
10. Helix Biopharma Closes $11.4 Million Private Placement
11. ARCA biopharma to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... ... April 20, 2017 , ... NetDimensions appoints Bill Mastin, a learning technology ... years of experience in the learning technologies industry, Mastin joins NetDimensions from the New ... Group plc (LTG). At LEO, Mastin served as SVP of the North America offices ...
(Date:4/20/2017)... MD (PRWEB) , ... April 20, 2017 , ... ... the formation of a unique intellectual property (IP) sharing and commercialization model. , ... most promising inventions. A main component of this effort is bringing the IP ...
(Date:4/19/2017)... ... April 18, 2017 , ... ... has been a key device for generating monodisperse droplets of known diameters for ... and for generating monodisperse solid particles by drying monodisperse droplets. , The ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
Breaking Biology News(10 mins):